Uniqure B.V. buy tamam
Summary
This prediction ended on 18.09.15 with a price of €29.47. With a performance of 33.24% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Uniqure B.V. | -3.333% | -3.333% | -58.327% | -83.238% |
| iShares Core DAX® | 0.410% | -2.543% | 14.415% | 14.709% |
| iShares Nasdaq 100 | -2.154% | 4.721% | 33.222% | 52.436% |
| iShares Nikkei 225® | -0.066% | -0.307% | 8.496% | 3.743% |
| iShares S&P 500 | -0.527% | 3.848% | 28.621% | 47.348% |
Comments by tamam for this prediction
In the thread Uniqure B.V. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
Uniqure NV ist ein führendes Unternehmen auf dem Gebiet der Gentherapie und hat mit Glybera das erste und derzeit einzige Gentherapieprodukt entwickelt und eine Zulassung in der Europäischen Union erhalten.
Glybera wird angewendet bei Erwachsenen, bei denen eine familiäre Lipoproteinlipasedefizienz (LPLD) diagnostiziert wurde und bei denen schwere oder multiple Pankreatitis-Schübe trotz fettarmer Ernährung aufgetreten sind.
Bristol-Myers Squibb (NYSE:BMY) purchases 1.3M ordinary shares of uniQure (NASDAQ:QURE) at $29.67 per share, a 26% premium over the Friday's closing price, raising its stake to 9.9%. In addition, it selects three new collaboration targets which triggers a $15M cash payment to uniQure.The collaboration agreement, signed on May 21, provides BMY exclusive access to uniQure's gene therapy technology platform for multiple targets in cardiovascular diseases. The deal includes uniQure's gene therapy program for congestive heart failure that is designed to restore the heart's ability to synthesize S100A1, a calcium sensor and master regulator of heat function.BMY has already made total payments to uniQure of $140M. The latter is eligible to receive additional milestones, including up to $254M for the S100A1 therapeutic, up to $217M for each other gene therapy product developed under the partnership and tiered single- and double-digit royalties on commercial sales. BMY also owns two warrants, each to acquire up to an additional 5% equity in uniQure, at a premium, based on additional targets being introduced into the collaboration. Under a separate supply contract, uniQURE will manufacture all gene therapy products under the agreement.